(c) 2024 PillSync.com

everolimus tablet

1 INDICATIONS AND USAGE Everolimus tablets are a kinase inhibitor indicated for the treatment of: • Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) • Adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use : Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) • Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are a kinase inhibitor indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer Everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. 1.2 Neuroendocrine Tumors (NET) Everolimus tablets are indicated for the treatment of adult patients with progressive, well-differentiated, non-functional NET of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. Limitations of Use : Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors [see Clinical Studies (14.2) ]. 1.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma Everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery. 1.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) Everolimus tablets are indicated in adult and pediatric patients aged 1 year and older with TSC for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected.

mylan pharmaceuticals inc.


4 years ago OVAL WHITE M EVR2 everolimus tablet

OVAL WHITE M EVR2

16 HOW SUPPLIED/STORAGE AND HANDLING

EVEROLIMUS Tablets are available containing 2.5 mg, 5 mg, 7.5 mg or 10 mg of

EVEROLIMUS. The 2.5 mg tablets are white to slightly yellow, capsule shaped, unscored tablets debossed with M on one side of the tablet and EVR2 on the other side. They are available as follows: NDC 0378-3096-28 bottles of 28 tablets NDC 0378-3096-85 cartons of 28 tablets The 5 mg tablets are white to slightly yellow, capsule shaped, unscored tablets debossed with M on one side of the tablet and EVR5 on the other side. They are available as follows: NDC 0378-3097-28 bottles of 28 tablets NDC 0378-3097-85 cartons of 28 tablets The 7.5 mg tablets are white to slightly yellow, capsule shaped, unscored tablets debossed with M on one side of the tablet and EVR7 on the other side. They are available as follows: NDC 0378-3098-28 bottles of 28 tablets NDC 0378-3098-85 cartons of 28 tablets The 10 mg tablets are white to slightly yellow, capsule shaped, unscored tablets debossed with M on one side of the tablet and EVR10 on the other side. They are available as follows: NDC 0378-3099-28 bottles of 28 tablets NDC 0378-3099-85 cartons of 28 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Store in the original container, protect from light and moisture. Follow special handling and disposal procedures for anti-cancer pharmaceuticals. 1


More pills like OVAL M EVR2

Related Pills

everolimus 10 mg

mylan pharmaceuticals inc.

everolimus tablet

mylan pharmaceuticals inc.

everolimus tablet

mylan pharmaceuticals inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site